Peter Nolan Purchases 249,687 Shares of Oxford BioMedica plc (LON:OXB) Stock

Oxford BioMedica plc (LON:OXB) insider Peter Nolan acquired 249,687 shares of Oxford BioMedica plc stock in a transaction dated Monday, July 17th. The stock was purchased at an average price of GBX 8 ($0.10) per share, with a total value of £19,974.96 ($26,022.62).

Receive News & Ratings for Oxford BioMedica plc Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.

Oxford BioMedica plc (LON OXB) opened at 8.58 on Friday. The stock has a 50 day moving average price of GBX 7.58 and a 200 day moving average price of GBX 5.41. Oxford BioMedica plc has a 52 week low of GBX 2.98 and a 52 week high of GBX 11.50. The stock’s market capitalization is GBX 264.61 million.

COPYRIGHT VIOLATION WARNING: This news story was first posted by [[site]] and is the property of of [[site]]. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at [[permalink]].

Several brokerages have recently issued reports on OXB. N+1 Singer raised their price objective on Oxford BioMedica plc from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) and gave the stock a “hold” rating in a research note on Thursday. Shore Capital restated a “not rated” rating on shares of Oxford BioMedica plc in a research note on Thursday, July 13th. Finally, Jefferies Group LLC restated a “buy” rating and issued a GBX 13 ($0.17) price objective on shares of Oxford BioMedica plc in a research note on Thursday, July 13th.

About Oxford BioMedica plc

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.